CN108186628A - A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof - Google Patents
A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof Download PDFInfo
- Publication number
- CN108186628A CN108186628A CN201810255470.0A CN201810255470A CN108186628A CN 108186628 A CN108186628 A CN 108186628A CN 201810255470 A CN201810255470 A CN 201810255470A CN 108186628 A CN108186628 A CN 108186628A
- Authority
- CN
- China
- Prior art keywords
- simvastatin
- ezetimibe
- dispersible tablet
- parts
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of dispersible tablets containing Ezetimibe and Simvastatin, include the component of following mass parts：0.5~2 part of 5~10 parts of Ezetimibe, 5~40 parts of Simvastatin, 40~80 parts of filler, 5~50 parts of disintegrant, 1~5 part of solubilizer, 1~5 part of lubricant and corrigent.The present invention is by the way that Ezetimibe, Simvastatin, filler, disintegrant, solubilizer, lubricant and corrigent are combined, and using specific proportioning, obtains a kind of dispersible tablet, each component collective effect, improves the dissolution rate of Ezetimibe and Simvastatin.In addition, the dispersible tablet provided by the present invention containing Ezetimibe and Simvastatin has excellent stability.
Description
Technical field
The present invention relates to pharmaceutical technology field more particularly to a kind of dispersible tablet containing Ezetimibe and Simvastatin and its
Preparation method.
Background technology
Cardiovascular and cerebrovascular disease is to endanger one of most common, most serious disease of the mankind's (the particularly middle-aged and the old) health.It is high
Atherosclerosis caused by blood fat, and further the cardiovascular and cerebrovascular diseases such as caused hypertension, coronary heart disease are dead as causing
The main reason for dying.Fat regulation medicine can reduce the incidence and the death rate of these diseases, the prevention of angiocardiopathy be generated positive
Effect.
Ezetimibe (Ezetimibe) chemical name is 1- (4- fluorophenyls) -3 (R)-[- 3 (S)-hydroxyls of 3- (4- fluorophenyls)
Propyl] -4 (S)-(4- hydroxyphenyls) -2- azetidines (azetidine) ketone), it is a kind of selective cholesterol absorption inhibitor,
The main exogenous absorption features for blocking cholesterol.It reduces release of the cholesterol to liver, so that gall dirty cholesterol
Storage is reduced, and the synthesis of liver low-density lipoprotein (LDL) receptor is caused to increase, and is accelerated LDL metabolism, is made plasma low density lipoprotein
Cholesterol (LDL-C) is horizontal to be reduced, so as to play the effect for the treatment of.Ezetimibe f hardlyes pass through cytochrome P 450 enzymes generation
It thanks, interacts between other drugs few, safety and tolerance are good.The half-life period of Ezetimibe is 22 hours, is taken daily
With 10mg, cholesterol absorption average out to 54% can be inhibited, low density lipoprotein cholesterol (LDL-C) can be made to reduce by 18% left
It is right.
Simvastatin (Simvastatin) chemical name for 2- acid dimethyls -8- [(4R, 6R) -6-2- [(1S, 2S,
6S, 8S, 8aR) -1,2,6,7,8,8a- hexahydro-8-hydroxy -2,6- dimethyl -1- naphthalenes] ethyl tetrahydrochysene -4- hydroxyl -2H- pyrroles
Mutter -2- ketone] ester), it is a kind of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor.Simvastatin can
Low density lipoprotein cholesterol (LDL-C) and triacylglycerol (TG) are reduced, increases high-density lipoprotein cholesterol (HDL-C).It should
Medication effect is high, Small side effects, it has also become the most common a kind of hypolipidemic in the whole world.
In order to improve blood fat compliance rate, while the incidence of adverse reaction is reduced, improve the quality of life of patient, inhomogeneity
The use in conjunction of other fat regulation medicine is a rational approach.Representative is Simvastatin and Ezetimibe drug combination.
Statins and Ezetimibe use in conjunction can respectively from the inside and outside source sexual approach of cholesterol blood lipid level is adjusted with
Reaching best regulating lipid, Ezetimibe is not metabolized by cytochrome P 450 Enzyme, therefore to the medicines of statins for power
Do not make significant difference；And statins smaller dose and Ezetimibe use in conjunction can reach the effect of satisfactory and
The risk of adverse reaction generation will not be increased；Ezetimibe can also compensate for the limitation of statins to a certain extent.
Therefore statins joint Ezetimibe can help more high-risk/high danger patients with lipid up to standard.
But Ezetimibe and Simvastatin belong to low-solubility, high osmosis drug, dissolution rate limits slowly
Drug fully absorbing and utilize in vivo.Drug at present containing Ezetimibe and Simvastatin is conventional tablet and capsule
Agent, the instant effect of the two is poor, and is not suitable for swallowing Patients with Difficult use.
Invention content
The purpose of the present invention is to provide a kind of dispersible tablets containing Ezetimibe and Simvastatin and preparation method thereof.This
The dispersible tablet containing Ezetimibe and Simvastatin that invention provides has the high advantage of dissolution rate.
The present invention provides a kind of dispersible tablets containing Ezetimibe and Simvastatin, include the component of following mass parts：
Preferably, the dispersible tablet containing Ezetimibe and Simvastatin includes the component of following mass parts：
Preferably, the filler is lactose, sorbierite, mannitol, sucrose, microcrystalline cellulose, starch and pregelatinated form sediment
At least one of powder.
Preferably, the disintegrant is sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone
At least one of with croscarmellose sodium.
Preferably, the solubilizer is at least one of lauryl sodium sulfate and poloxamer.
Preferably, the lubricant is at least one of magnesium stearate, talcum powder and superfine silica gel powder.
Preferably, the corrigent is at least one of aspartame, glycyrrhizin and essence
The present invention also provides the dispersible tablets containing Ezetimibe and Simvastatin described in a kind of above-mentioned technical proposal
Preparation method includes the following steps：
(1) lubricant of Ezetimibe, Simvastatin, filler, disintegrant, solubilizer and 55~65% recipe quantities is mixed
After conjunction, dry granulation is carried out, obtains compound particles；
(2) by tabletting after the compound particles and corrigent, remaining mix lubricant, obtain containing Ezetimibe with
The dispersible tablet of Simvastatin.
Preferably, the grain size of the Ezetimibe and Simvastatin independently is 40~120 μm.
Preferably, the mesh of the grain size of the hybrid particles≤20.
The present invention provides a kind of dispersible tablets containing Ezetimibe and Simvastatin, include the component of following mass parts：
5~10 parts of Ezetimibe, 5~40 parts of Simvastatin, 40~80 parts of filler, 5~50 parts of disintegrant, 1~5 part of solubilizer, profit
0.5~2 part of 1~5 part of lubrication prescription and corrigent.The present invention is by by Ezetimibe, Simvastatin, filler, disintegrant, solubilising
Agent, lubricant and corrigent combination, and using specific proportioning, obtain a kind of dispersible tablet, each component collective effect, improve according to
The dissolution rate of Ezetimibe and Simvastatin.
The experimental results showed that it is in pH value by the dispersible tablet provided by the present invention containing Ezetimibe and Simvastatin
Test Ezetimibe and Simvastatin is molten in 4.5 phosphate buffer solution+0.2wt.% neopelexes (SDS)
Out-degree, Ezetimibe and Simvastatin, which focus primarily upon, to be dipped in after dissolution medium in the period of 5~15min, in 10min,
The dissolution rate of Ezetimibe and Simvastatin can reach more than 75%, and the dissolution rate of the two approaches, and have similar
Dissolution profiles are conducive to preferably play synergistic effect；In addition, containing Ezetimibe and pungent cut down him by provided by the present invention
The dispersible tablet in spit of fland have excellent stability, place it in temperature be 40 ± 2 DEG C with humidity be in 75 ± 5% constant temperature and humidity phase
It places 6 months, the composition of dissolution rate and dispersible tablet of the test dispersible tablet when dissolving out 15min, the results showed that place 6 months
Afterwards, the dissolution rate when dissolving out 15min does not change, and the composition of product does not also change；It is also, provided by the present invention
The dispersible tablet containing Ezetimibe and Simvastatin can disperse rapidly into the water after take, carry it is easy to use, especially just
Just old man, children and swallow Patients with Difficult use.
Specific embodiment
The present invention provides a kind of dispersible tablets containing Ezetimibe and Simvastatin, include the component of following mass parts：
In the present invention, in terms of mass parts, the dispersible tablet containing Ezetimibe and Simvastatin includes Ezetimibe 5
~10 parts, preferably 7~9 parts.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland includes 5~40 parts of Simvastatin, more preferably preferably 15~30 parts, 20~25 parts.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland includes 40~80 parts of filler, more preferably preferably 55~70 parts, 60~65 parts.
In the present invention, the filler be preferably lactose, sorbierite, mannitol, sucrose, microcrystalline cellulose, starch and
At least one of pregelatinized starch.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland includes 5~50 parts of disintegrant, more preferably preferably 15~35 parts, 20~25 parts.
In the present invention, the disintegrant is preferably sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked polyethylene
At least one of pyrrolidones and croscarmellose sodium.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland include 1~5 part of solubilizer, more preferably 2~3 parts.
In the present invention, the solubilizer is preferably at least one of lauryl sodium sulfate and poloxamer.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland include 1~5 part of lubricant, preferably 2~4 parts.In the present invention, the lubricant is conducive to improve material
Mobility makes material mixing evenly.
In the present invention, the lubricant is preferably at least one of magnesium stearate, talcum powder and superfine silica gel powder.
In the present invention, it is described containing Ezetimibe and pungent to cut down him by the parts by weight of Ezetimibe on the basis of 5~10 parts
The dispersible tablet in spit of fland include 0.5~2 part of corrigent, preferably 1~1.5 part.
In the present invention, the corrigent is preferably at least one of aspartame, glycyrrhizin and essence.
The present invention also provides the dispersible tablets containing Ezetimibe and Simvastatin described in a kind of above-mentioned technical proposal
Preparation method includes the following steps：
(1) lubricant of Ezetimibe, Simvastatin, filler, disintegrant, solubilizer and 55~65% recipe quantities is mixed
After conjunction, through dry granulation, compound particles are obtained；
(2) it by after the compound particles and corrigent, remaining mix lubricant, through tabletting, obtains containing according to folding wheat
The dispersible tablet of cloth and Simvastatin.
The present invention is by the lubrication of Ezetimibe, Simvastatin, filler, disintegrant, solubilizer and 55~65% recipe quantities
After agent mixing, through dry granulation, compound particles are obtained.
In the present invention, the grain size of the Ezetimibe and Simvastatin is preferably independently 40~120 μm.When it is described according to
The grain size of Ezetimibe and Simvastatin not within the above range when, preferably by the Ezetimibe and Simvastatin micronizing after again
It uses；The present invention is not particularly limited the mode of the micronizing, can obtain needed for grain size Ezetimibe and pungent cut down him
Spit of fland.In the present invention, the Ezetimibe of above-mentioned grain size and Simvastatin are conducive to dissolve out.
In the present invention, the grain size of the filler, disintegrant, solubilizer and corrigent independently preferably≤80 mesh；Institute
State grain size preferably≤40 mesh of lubricant.
The present invention does not have the hybrid mode in the preparation method of the dispersible tablet containing Ezetimibe and Simvastatin
Material can be uniformly mixed by particular determination；In embodiments of the present invention, the mixing is preferably pelletized in mixed at high speed
Machine mixes.
In embodiments of the present invention, the Ezetimibe, Simvastatin, filler, disintegrant, solubilizer and 55~65%
The mixing velocity of the lubricant of recipe quantity is preferably 35~45r/min, more preferably 40r/min；The time of the mixing is preferred
For 13~18min, more preferably 15min.
In the present invention, the grain size of the hybrid particles preferably≤20 mesh.In the present invention, the hybrid particles of above-mentioned grain size
The mobility and compressibility of material can be improved.
The present invention is not particularly limited the concrete technology of the dry granulation, can obtain the hybrid particles of required grain size
.In the present invention, the dry granulation is not needed to humidify and be dried, and has saved a large amount of electric energy；And adhesive need not be added,
Not only it is energy saving but also pollution-free；The dissolution rate of product can also be improved, is conducive to improve the bioavilability of drug.
After the completion of dry granulation, the present invention obtains compound particles preferably by gained pellet through sieves.
After obtaining compound particles, the present invention is passed through after the compound particles and corrigent, remaining mix lubricant
Tabletting obtains the dispersible tablet containing Ezetimibe and Simvastatin.
In embodiments of the present invention, the mixing rate of the compound particles and corrigent, remaining lubricant is preferably
25~30r/min, more preferably 30r/min.
The present invention is not particularly limited the shape of the tabletting, can have any shape.
The present invention is not particularly limited the design parameter of the tabletting, and those skilled in the art can be adjusted as needed
The parameter of tabletting.
Below in conjunction with the embodiment in the present invention, the technical solution in the present invention is clearly and completely described.It is aobvious
So, described embodiment is only part of the embodiment of the present invention, instead of all the embodiments.Based on the reality in the present invention
Apply example, those of ordinary skill in the art's all other embodiments obtained without making creative work all belong to
In the scope of protection of the invention.
Embodiment 1
(1) by Ezetimibe and Simvastatin, micro mist turns to the powder that grain size is 40~120 μm respectively, by lactose, carboxylic first
It is spare that base sodium starch, neopelex and aspartame cross 80 mesh sieve；It is spare that magnesium stearate is crossed into 40 mesh sieve；
(2) in parts by mass, by 5 parts of Ezetimibe, 10 parts of Simvastatin, 55 parts of lactose, 30 parts of sodium carboxymethyl starch, ten
1.2 parts of 2 parts of dialkyl benzene sulfonic acids sodium and magnesium stearate in high-speed mixing granulating machine with the rotating speed mixing 15min of 40r/min, so
Resulting material will be mixed afterwards successively through dry granulation, the sieve of 20 mesh excessively, obtain compound particles；
(3) by the compound particles and 0.5 part of aspartame, 0.8 part of neopelex in high-speed mixer
After the speed mixing 10min of 30r/min, through tabletting, the dispersible tablet containing Ezetimibe and Simvastatin is obtained.
Embodiment 2
(1) by Ezetimibe and Simvastatin, micro mist turns to the powder that grain size is 40~120 μm respectively, by sucrose, crosslinking
It is spare that sodium carboxymethylcellulose, poloxamer and the savory essence of orange cross 80 mesh sieve；It is spare that magnesium stearate is crossed into 40 mesh sieve；
(2) in parts by mass, by 10 parts of Ezetimibe, 30 parts of Simvastatin, 60 parts of sucrose, croscarmellose sodium
2.4 parts of 35 parts, 3 parts of poloxamer and magnesium stearate in high-speed mixing granulating machine with the rotating speed mixing 15min of 40r/min, so
Resulting material will be mixed afterwards successively through dry granulation, the sieve of 20 mesh excessively, obtain compound particles；
(3) by the compound particles with orange it is savory smart 1 part, 1.6 parts of magnesium stearate in high-speed mixer with 30r/min's
After speed mixing 10min, through tabletting, the dispersible tablet containing Ezetimibe and Simvastatin is obtained.
Embodiment 3
(1) by Ezetimibe and Simvastatin, micro mist turns to the powder that grain size is 40~120 μm respectively, by microcrystalline cellulose
It is spare that element, sodium carboxymethyl starch, poloxamer and aspartame cross 80 mesh sieve；It is spare that talcum powder is crossed into 40 mesh sieve；
(2) in parts by mass, by 8 parts of Ezetimibe, 20 parts of Simvastatin, 70 parts of microcrystalline cellulose, sodium carboxymethyl starch
1.2 parts of 25 parts, 3 parts of poloxamer and talcum powder in high-speed mixing granulating machine with the rotating speed mixing 15min of 40r/min, then
Resulting material will be mixed successively through dry granulation, the sieve of 20 mesh excessively, obtain compound particles；
(3) by the compound particles and 1 part of aspartame, 0.8 part of talcum powder in high-speed mixer with the speed of 30r/min
After degree mixing 10min, through tabletting, the dispersible tablet containing Ezetimibe and Simvastatin is obtained.
It is in pH value with common marketed tablet by the dispersible tablet containing Ezetimibe and Simvastatin obtained by Examples 1 to 3
In 4.5 phosphate buffer+0.2%SDS (containing the lauryl sodium sulfate that mass concentration is 0.2% i.e. in buffer solution)
It is dissolved out, tests the dissolution rate (i.e. stripping quantity) of different dissolution time points, the results are shown in Table 1.
Dispersible tablet containing Ezetimibe and Simvastatin obtained by 1 Examples 1 to 3 of table and the dissolution of common marketed tablet
Spend test result
The dissolution of the Ezetimibe and Simvastatin of dispersible tablet obtained by Examples 1 to 3 focuses primarily upon dissolution as shown in Table 1
Time is the period of 5-15min, and when dissolution time is 10min, the dissolution rate of Ezetimibe and Simvastatin is reachable
More than 75%, it is significantly higher than commercially available conventional tablet, is more advantageous to targeting and absorbs；And Ezetimibe and Simvastatin dissolution rate
It is close, there is similar stripping curve can preferably play synergistic effect.
By the dispersible tablet containing Ezetimibe and Simvastatin obtained by Examples 1 to 3 and common marketed tablet, it is placed in temperature
It to be placed 6 months in 40 ± 2 DEG C, the climatic chamber that humidity is 75 ± 5%, was sampled respectively at the 0th, 1,2,3,6 month, detection
Index is character, dispersing uniformity, dissolution rate (15min), related substance (i.e. impurity), Ezetimibe and Simvastatin content,
With the stability of test product, the results are shown in Table 2.Wherein dispersing uniformity, according to disintegration time limited inspection technique (Chinese Pharmacopoeia
Four general rules 0921 of version in 2015) it checks, the sieve pore internal diameter of stainless steel cloth is 710 μm, and water temperature is 15~25 DEG C；Take test sample
It 6, was all disintegrated in 3 minutes and passes through sieve.
Dispersible tablet containing Ezetimibe and Simvastatin obtained by 2 Examples 1 to 3 of table and the stabilization of common marketed tablet
Property test result
By the test result of table 2 it is found that dispersible tablet obtained by Examples 1 to 3 temperature be 40 ± 2 DEG C with humidity be 75 ±
It is placed 6 months in 5% constant temperature and humidity phase, the dissolution rate when dissolving out 15min does not change, and the composition of product is not also sent out
Changing；And the dissolution rate of common marketed tablet is then remarkably decreased with the extension of standing time, is illustrated obtained by Examples 1 to 3
The stability of dispersible tablet is better than common marketed tablet.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of dispersible tablet containing Ezetimibe and Simvastatin includes the component of following mass parts：
2. the dispersible tablet according to claim 1 containing Ezetimibe and Simvastatin, which is characterized in that including following matter
Measure the component of part：
3. the dispersible tablet according to claim 1 or 2 containing Ezetimibe and Simvastatin, which is characterized in that described to fill out
Agent is filled at least one of lactose, sorbierite, mannitol, sucrose, microcrystalline cellulose, starch and pregelatinized starch.
4. the dispersible tablet according to claim 1 or 2 containing Ezetimibe and Simvastatin, which is characterized in that described to collapse
Solution agent is sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone and croscarmellose sodium
At least one of.
5. the dispersible tablet according to claim 1 or 2 containing Ezetimibe and Simvastatin, which is characterized in that the increasing
Solvent is at least one of lauryl sodium sulfate and poloxamer.
6. the dispersible tablet according to claim 1 or 2 containing Ezetimibe and Simvastatin, which is characterized in that the profit
Lubrication prescription is at least one of magnesium stearate, talcum powder and superfine silica gel powder.
7. the dispersible tablet according to claim 1 or 2 containing Ezetimibe and Simvastatin, which is characterized in that described to rectify
Taste agent is at least one of aspartame, glycyrrhizin and essence.
8. a kind of claim 1~7 any one of them contains the preparation method of the dispersible tablet of Ezetimibe and Simvastatin, packet
Include following steps：
(1) by the mix lubricant of Ezetimibe, Simvastatin, filler, disintegrant, solubilizer and 55~65% recipe quantities
Afterwards, dry granulation is carried out, obtains compound particles；
(2) it by tabletting after the compound particles and corrigent, remaining mix lubricant, obtains containing Ezetimibe and pungent cuts down
The dispersible tablet of statin.
9. preparation method according to claim 8, which is characterized in that the grain size of the Ezetimibe and Simvastatin is independent
Ground is 40~120 μm.
10. preparation method according to claim 8, which is characterized in that the mesh of the grain size of the hybrid particles≤20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810255470.0A CN108186628A (en) | 2018-03-26 | 2018-03-26 | A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810255470.0A CN108186628A (en) | 2018-03-26 | 2018-03-26 | A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108186628A true CN108186628A (en) | 2018-06-22 |
Family
ID=62596176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810255470.0A Pending CN108186628A (en) | 2018-03-26 | 2018-03-26 | A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108186628A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451161A (en) * | 2010-10-18 | 2012-05-16 | 王丽燕 | Dispersible tablets containing cholesterol absorption inhibitor and lipid regulating drug, and application thereof |
-
2018
- 2018-03-26 CN CN201810255470.0A patent/CN108186628A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451161A (en) * | 2010-10-18 | 2012-05-16 | 王丽燕 | Dispersible tablets containing cholesterol absorption inhibitor and lipid regulating drug, and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2359811B1 (en) | Dried milled granulate and methods | |
| EP2422783B1 (en) | Pharmaceutical Composition | |
| US7732492B2 (en) | Nateglinide-containing preparation | |
| US20170340569A1 (en) | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases | |
| CN103655481A (en) | Preparation method of ezetimibe orally-taken preparation | |
| CN103877051B (en) | A kind of preparation method of Ezetimibe sheet | |
| CN105935358A (en) | Sacubitril / valsartan sustained release agent and preparation method thereof | |
| GB2595140A (en) | Flupentixol/melitracen pharmaceutical composition and preparation thereof | |
| IL170507A (en) | Method for production of a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method | |
| CN106491554A (en) | A kind of Atorvastatin Calcium Tablets agent and preparation method thereof | |
| JP4730985B2 (en) | Stabilized pharmaceutical formulation | |
| CN104127391B (en) | A kind of contain Atorvastatin calcium solid composite medicament | |
| CN103239725A (en) | Compound preparation for treating cardiovascular and cerebrovascular diseases | |
| CN105682642A (en) | Pharmaceutical compositions of ranolazine and dronedarone | |
| CN108186628A (en) | A kind of dispersible tablet containing Ezetimibe and Simvastatin and preparation method thereof | |
| CN102266323B (en) | Composition of ezetimibe and simvastatin and preparation method thereof | |
| CN102008469A (en) | Method for preparing telmisartan amlodipine tablets | |
| CN105582546A (en) | Compound enteric-coated tablets of entecavir phospholipid complex and diammonium glycyrrhizinate | |
| KR101296328B1 (en) | Solid dispersant comprising fibrates and a method for preparing the same | |
| CN101574345A (en) | Compound simvastatin niacin sustained release tablet and preparation method thereof | |
| CN106822020A (en) | A kind of Ezetimibe tablet | |
| JP6993765B2 (en) | Film-coated tablets with a smooth surface | |
| CN102424653B (en) | Fenofibrate compound and atorvastatin calcium fenofibrate pharmaceutical composition thereof | |
| CN103705489B (en) | Bezafibrate dual-release slow-release capsule medicinal composition | |
| RU2796502C1 (en) | Cellulose-containing composition, tablet and tablet with intraoral disintegration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180622 |